MARIMED INC

For the period ended Dec 31, 2024. Filed Mar 6, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 6, 2025

MRMDStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Common stock · Common stock subscribed but not issued · Additional paid-in capital · Accumulated deficit · Non-controlling interests · Total stockholders' equity
Shares · Par Value · Shares · Amount
Balances at January 1, 2023	341,474,728	$341		70,000		$39		$142,365		$(83,924)		$(1,511)		$57,310
Common stock subscribed but not issued	—	—		5,025		2		—		—		—		2
Issuance of subscribed shares	75,025	—		(75,025)		(41)		41		—		—		—
Release of shares under stock grants	599,999	1		—		—		(1)		—		—		—
Exercise of stock options	487,752	—		—		—		109		—		—		109
Warrants issued in connection with debt	—	—		—		—		5,454		—		—		5,454
Conversion of preferred stock to common stock	25,304,710	25		—		—		18,700		—		—		18,725
Common stock issued to settle obligations	400,000	—		—		—		160		—		—		160
Common stock issued under a licensing and royalty agreement	13,007	—		—		—		5		—		—		5
Common stock issued to purchase property and equipment	740,741	1		—		—		299		—		—		300
Common stock issued as purchase consideration - business acquisition	6,580,390	7		—		—		2,987		—		—		2,994
Purchase of minority interest in a subsidiary of the Company	450,000	1		—		—		4		—		(5)		—
Common stock returned to the Company in connection with a cancelled transaction (1)	(1,000,000)	(1)		—		—		1		—		—		—
Distributions to noncontrolling interests	—	—		—		—		—		—		(158)		(158)
Stock-based compensation	—	—		—		—		1,020		—		—		1,020
Net (loss) income	—	—		—		—		—		(16,031)		24		(16,007)
Balances at December 31, 2023	375,126,352	$375		—		$—		$171,144		$(99,955)		$(1,650)		$69,914
Release of shares under stock grants	2,636,750	2		—		—		(2)		—		—		—
Shares of newly vested common stock surrendered to the Company to satisfy tax withholding obligations	(249,087)	—		—		—		(41)		—		—		(41)
Standalone warrants issued as payment for services	—	—		—		—		218		—		—		218
Common stock issued under a licensing and royalty agreement	45,299	—		—		—		10		—		—		10
Common stock issued as purchase consideration - business acquisition	3,917,267	4		—		—		987		—		—		991
Distributions to noncontrolling interests	—	—		—		—		—		—		(139)		(139)
Stock-based compensation	—	—		—		—		1,050		—		—		1,050
Net (loss) income	—	—		—		—		—		(12,164)		37		(12,127)
Balances at December 31, 2024	381,476,581		$381		—		$—		$173,366		$(112,119)		$(1,752)		$59,876

(1)Represents shares initially issued in connection with an acquisitive transaction that was subsequently cancelled, at which time the shares were returned to the Company and recorded at par value.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.